• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of aacPermissionsJournals.ASM.orgJournalAAC ArticleJournal InfoAuthorsReviewers
Antimicrob Agents Chemother. Oct 1996; 40(10): 2296–2299.
PMCID: PMC163523

Bactericidal action of ofloxacin, sulbactam-ampicillin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis.

Abstract

The bactericidal actions of ofloxacin and sulbactam-ampicillin, alone and in combination with rifampin and isoniazid, on exponential-phase and stationary-phase cultures of a drug-susceptible isolate of Mycobacterium tuberculosis were studied in vitro. In exponential-phase cultures, all drugs were bactericidal, with the higher concentrations of ofloxacin (5 micrograms/ml) and sulbactam-ampicillin (15 micrograms of ampicillin per ml) being as bactericidal as 1 microgram of isoniazid per ml or 1 microgram of rifampin per ml. In two-drug combinations, both drugs increased the levels of activity of isoniazid and rifampin and were almost as bactericidal as isoniazid-rifampin; they also appeared to increase the level of activity of isoniazid-rifampin in three-drug combinations. In contrast, ofloxacin and sulbactam-ampicillin had little bactericidal activity against stationary-phase cultures and were less active than isoniazid or rifampin alone. Furthermore, in two-drug or three-drug combinations, they did not increase the level of activity of isoniazid, rifampin, or isoniazid-rifampin. These findings suggest that ofloxacin and sulbactam-ampicillin are likely to be most useful in the early stages of treatment and in preventing the emergence of resistance to other drugs but are unlikely to be effective as sterilizing drugs helping to kill persisting lesional bacilli.

Full Text

The Full Text of this article is available as a PDF (214K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Bush K. Beta-lactamase inhibitors from laboratory to clinic. Clin Microbiol Rev. 1988 Jan;1(1):109–123. [PMC free article] [PubMed]
  • DeMaio J, Zhang Y, Ko C, Young DB, Bishai WR. A stationary-phase stress-response sigma factor from Mycobacterium tuberculosis. Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2790–2794. [PMC free article] [PubMed]
  • Dickinson JM, Mitchison DA. Experimental models to explain the high sterilizing activity of rifampin in the chemotherapy of tuberculosis. Am Rev Respir Dis. 1981 Apr;123(4 Pt 1):367–371. [PubMed]
  • Dickinson JM, Mitchison DA. In vitro activities against mycobacteria of two long-acting rifamycins, FCE22807 and CGP40/469A (SPA-S-565). Tubercle. 1990 Jun;71(2):109–115. [PubMed]
  • Foulds G. Pharmacokinetics of sulbactam/ampicillin in humans: a review. Rev Infect Dis. 1986 Nov-Dec;8 (Suppl 5):S503–S511. [PubMed]
  • Heifets LB, Lindholm-Levy PJ. Bacteriostatic and bactericidal activity of ciprofloxacin and ofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. Tubercle. 1987 Dec;68(4):267–276. [PubMed]
  • HOBBY GL, LENERT TF. The in vitro action of antituberculous agents against multiplying and non-multiplying microbial cells. Am Rev Tuberc. 1957 Dec;76(6):1031–1048. [PubMed]
  • Jindani A, Aber VR, Edwards EA, Mitchison DA. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis. 1980 Jun;121(6):939–949. [PubMed]
  • Lalande V, Truffot-Pernot C, Paccaly-Moulin A, Grosset J, Ji B. Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice. Antimicrob Agents Chemother. 1993 Mar;37(3):407–413. [PMC free article] [PubMed]
  • Mitchison DA. The action of antituberculosis drugs in short-course chemotherapy. Tubercle. 1985 Sep;66(3):219–225. [PubMed]
  • Mitchison DA. The Garrod Lecture. Understanding the chemotherapy of tuberculosis--current problems. J Antimicrob Chemother. 1992 May;29(5):477–493. [PubMed]
  • Mitchison DA. Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. Am Rev Respir Dis. 1993 Apr;147(4):1062–1063. [PubMed]
  • Nadler JP, Berger J, Nord JA, Cofsky R, Saxena M. Amoxicillin-clavulanic acid for treating drug-resistant Mycobacterium tuberculosis. Chest. 1991 Apr;99(4):1025–1026. [PubMed]
  • Prabhakaran K, Harris EB, Randhawa B, Hastings RC. Reversal of drug resistance in Mycobacterium leprae by ampicillin/sulbactam. Microbios. 1992;72(291):137–142. [PubMed]
  • Ripa S, Ferrante L, Prenna M. Pharmacokinetics of sulbactam/ampicillin in humans after intravenous and intramuscular injection. Chemotherapy. 1990;36(3):185–192. [PubMed]
  • Sorg TB, Cynamon MH. Comparison of four beta-lactamase inhibitors in combination with ampicillin against Mycobacterium tuberculosis. J Antimicrob Chemother. 1987 Jan;19(1):59–64. [PubMed]
  • Tsukamura M. In vitro antituberculosis activity of a new antibacterial substance ofloxacin (DL8280). Am Rev Respir Dis. 1985 Mar;131(3):348–351. [PubMed]
  • Tsukamura M. Antituberculosis activity of ofloxacin (DL 8280) on experimental tuberculosis in mice. Am Rev Respir Dis. 1985 Oct;132(4):915–915. [PubMed]
  • Wayne LG. Dormancy of Mycobacterium tuberculosis and latency of disease. Eur J Clin Microbiol Infect Dis. 1994 Nov;13(11):908–914. [PubMed]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...